Electrocore, INC 10-Q quarterly reports

electroCore, Inc. reported increased net sales for Q2 2026, but continued operating losses and a significant cash burn have raised substantial doubt about its ability to continue as a going concern.

electroCore reported a 33% increase in Q3 net sales to $8.7 million, driven by prescription and wellness products, but net loss widened to $3.4 million as operating expenses rose.

electroCore, Inc. reported a 20% increase in net sales for Q2 2025, reaching $7.38 million, but net losses widened to $3.67 million, alongside a significant decline in cash and marketable securities.

electroCore's Q1 2025 net sales increased by 23% year-over-year, driven by growth in VA sales and Truvaga product revenue.

electroCore, Inc. reports a 45% increase in net sales for the third quarter of 2024 compared to the same period last year, driven by growth across multiple channels.

electroCore, Inc. saw a significant 73% increase in net sales in Q2 2024 compared to Q2 2023, driven by growth across multiple channels, and has alleviated concerns about its ability to continue as a going concern.

electroCore, Inc. saw a 96% increase in net sales in the first quarter of 2024, primarily driven by growth in government channels and the introduction of new wellness products.